公开(公告)号：US20210169865A1

公开(公告)日：2021-06-10

申请号：US17178609

申请日：2021-02-18

申请人： Genentech, Inc. ,  Board of Regents, The University of Texas System

发明人： Mark Merchant ,  Deepak Sampath ,  Marina Konopleva ,  Lina Han

IPC分类号： A61K31/4523 ,  A61K45/06 ,  A61K31/496 ,  A61P35/02

摘要： The present invention is directed to a combination therapy involving a selective Bcl-2 inhibitor and a MEK inhibitor for the treatment of a patient in need of such a therapy. The patient in need of the combination therapy is suffering from cancer, such as acute myeloid leukemia.

公开(公告)号：US09532987B2

公开(公告)日：2017-01-03

申请号：US14473311

申请日：2014-08-29

申请人： Genentech, Inc.

发明人： Marcia Belvin ,  John Moffat ,  Mark Merchant

IPC分类号： A61K31/506 ,  A61K31/397 ,  A61K31/435 ,  A61K31/437 ,  A61K31/5025

CPC分类号： A61K31/506 ,  A61K31/397 ,  A61K31/435 ,  A61K31/437 ,  A61K31/5025 ,  A61K2300/00

摘要： The invention provides combinations comprising a MEK inhibitor (such as GDC-0973 or GDC-0623), or a pharmaceutically acceptable salt thereof and an ERK inhibitor (such as GDC-0994). The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.

摘要翻译： 本发明提供了包含MEK抑制剂（例如GDC-0973或GDC-0623）或其药学上可接受的盐和ERK抑制剂（例如GDC-0994）的组合。 这些组合对于治疗过度增殖性疾病如癌症特别有用。

公开(公告)号：US20180303815A1

公开(公告)日：2018-10-25

申请号：US15767914

申请日：2016-11-03

申请人： Genentech, Inc. ,  Board of Regents, The University of Texas System

发明人： Mark Merchant ,  Deepak Sampath ,  Marina Konopleva ,  Lina Han

IPC分类号： A61K31/4523 ,  A61P35/02

CPC分类号： A61K31/4523 ,  A61K31/496 ,  A61K45/06 ,  A61K2300/00 ,  A61P35/02

摘要： The present invention is directed to a combination therapy involving a selective Bcl-2 inhibitor and a MEK inhibitor for the treatment of a patient in need of such a therapy. The patient in need of the combination therapy is suffering from cancer, such as acute myeloid leukemia.

公开(公告)号：US20150111869A1

公开(公告)日：2015-04-23

申请号：US14473311

申请日：2014-08-29

申请人： Genentech, Inc.

发明人： Marcia Belvin ,  John Moffat ,  Mark Merchant

IPC分类号： A61K31/506 ,  A61K31/397

CPC分类号： A61K31/506 ,  A61K31/397 ,  A61K31/435 ,  A61K31/437 ,  A61K31/5025 ,  A61K2300/00

摘要： The invention provides combinations comprising a MEK inhibitor (such as GDC-0973 or GDC-0623), or a pharmaceutically acceptable salt thereof and an ERK inhibitor (such as GDC-0994). The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.

摘要翻译： 本发明提供了包含MEK抑制剂（例如GDC-0973或GDC-0623）或其药学上可接受的盐和ERK抑制剂（例如GDC-0994）的组合。 这些组合对于治疗过度增殖性疾病如癌症特别有用。

公开(公告)号：US20210332143A1

公开(公告)日：2021-10-28

申请号：US17249530

申请日：2021-03-04

申请人： Genentech, Inc.

发明人： Mahrukh Huseni ,  Joanna E. Klementowicz ,  Yijin Li ,  Li-Fen Liu ,  Sanjeev Mariathasan ,  Mark Merchant ,  Luciana Molinero ,  Lifen Wang ,  Nathaniel West ,  Patrick Williams ,  Chi Yung Yuen ,  Edward Namserk Cha ,  Yulei Wang

IPC分类号： C07K16/28 ,  A61P35/00 ,  A61K31/337 ,  A61K47/64

摘要： This application discloses methods and compositions for use in treating cancer, including breast cancer (such as metastatic triple negative breast cancer, mTNBC), urothelial carcinoma, renal cell carcinoma, and liver cancer (hepatocellular carcinoma, HCC) with the combination of a PD-1 axis binding antagonist (e.g., a PD-L1 binding antibody such as atezolizumab) and an IL6 antagonist (e.g. an anti-IL6 receptor antibody such as tocilizumab), optionally further comprising a VEGF antagonist (e.g. an anti-VEGF antibody such as bevacizumab). Optionally, the patient has C-reactive protein (CRP) and/or IL-6 level(s) above the upper limit of normal. Optionally, the cancer is PD-L1 positive.

公开(公告)号：US20130078252A1

公开(公告)日：2013-03-28

申请号：US13622878

申请日：2012-09-19

申请人： Genentech, Inc.

发明人： Timothy R. Wilson ,  Hartmut Koeppen ,  Mark Merchant ,  Jeffrey Settleman

IPC分类号： A61K39/00 ,  A61K31/437 ,  A61K39/395 ,  G01N33/74 ,  G01N33/573 ,  A61K31/4545 ,  A61K31/4439 ,  C12Q1/68 ,  G01N33/574

CPC分类号： A61K39/3955 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/4545 ,  A61K45/06 ,  C07K16/2863 ,  C07K16/3053 ,  C07K2317/75 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/5091 ,  G01N33/573 ,  G01N33/5748 ,  G01N33/57488 ,  G01N33/57496 ,  G01N33/6872 ,  G01N33/74 ,  G01N2800/52 ,  A61K2300/00 ,  A61K39/39558

摘要： The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological conditions, such as cancer.

公开(公告)号：US10959993B2

公开(公告)日：2021-03-30

申请号：US15767914

申请日：2016-11-03

申请人： Genentech, Inc. ,  Board of Regents, The University of Texas System

发明人： Mark Merchant ,  Deepak Sampath ,  Marina Konopleva ,  Lina Han

IPC分类号： A61K31/5365 ,  A61K31/497 ,  A61K31/4523 ,  A61K45/06 ,  A61K31/496 ,  A61P35/02

摘要： The present invention is directed to a combination therapy involving a selective Bcl-2 inhibitor and a MEK inhibitor for the treatment of a patient in need of such a therapy. The patient in need of the combination therapy is suffering from cancer, such as acute myeloid leukemia.

公开(公告)号：US20150125452A1

公开(公告)日：2015-05-07

申请号：US14535071

申请日：2014-11-06

申请人： GENENTECH, INC.

发明人： Timothy R. Wilson ,  Hartmut Koeppen ,  Mark Merchant ,  Jeffrey Settleman

IPC分类号： A61K39/395 ,  G01N33/574 ,  C12Q1/68 ,  A61K31/437 ,  A61K31/4545

CPC分类号： A61K39/3955 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/4545 ,  A61K45/06 ,  C07K16/2863 ,  C07K16/3053 ,  C07K2317/75 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/5091 ,  G01N33/573 ,  G01N33/5748 ,  G01N33/57488 ,  G01N33/57496 ,  G01N33/6872 ,  G01N33/74 ,  G01N2800/52 ,  A61K2300/00 ,  A61K39/39558

摘要： The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological conditions, such as cancer.

摘要翻译： 本发明一般涉及分子生物学和生长因子调节领域。 更具体地，本发明涉及用于治疗诸如癌症的病理状况的治疗。

公开(公告)号：US20150056207A1

公开(公告)日：2015-02-26

申请号：US14198359

申请日：2014-03-05

申请人： Genentech, Inc.

发明人： Ellen Filvaroff ,  Mark Merchant ,  Robert L. Yauch

IPC分类号： A61K31/517 ,  A61K45/06 ,  C12N15/113 ,  A61K39/395

CPC分类号： A61K31/517 ,  A61K31/5377 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C12N15/1135 ,  C12N2310/122 ,  C12N2320/31 ,  A61K2300/00

摘要： The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to combination therapies for the treatment of pathological conditions, such as cancer.